Home › Compare › BPIRY vs ABBV
BPIRY yields 103.93% · ABBV yields 3.06%● Live data
📍 BPIRY pulled ahead of the other in Year 1
Combined, BPIRY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BPIRY + ABBV for your $10,000?
Piraeus Financial Holdings S.A. provides banking products and services in Greece and internationally. It operates through Retail Banking, Corporate Banking, Piraeus Financial Markets, and Other segments. The company offers time, structured, deposit, saving, current, and business accounts; mortgage, consumer, personal, home improvement, farming, restructuring, and working capital loans; overdrafts; credit, debit, contract farming, and prepaid cards; mutual funds, treasury bonds, equities, dual currency deposits, treasury interest-bearing notes, asset management solutions, and gold sovereigns and gold bars; and car, home, civil liability, health, endowment, accident/life, lifestyle, agricultural, photovoltaic park, trade credit, business premises, and corporate insurances. It also provides financial planning, payment/remittance, bills of exchange collection, cash management, import-export settlement, payroll, foreign exchange, risk management, letters of guarantee, factoring, leasing, and Web banking services. The company offers infrastructure advisory, project and real estate finance, remote banking service, group life and health and electronic and cyber risks insurance programs, debt collection, and contract farming. It operates 414 branches in Greece and another 16 branches in 2 countries. Piraeus Financial Holdings S.A. was formerly known as Piraeus Bank S.A. The company was founded in 1916 and is based in Athens, Greece.
Full BPIRY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.